Résumé
Childhood absence epilepsy (CAE) is a non-convulsive seizure disorder primarily in children characterized by absence seizures. Absence seizures consist of 2.5–5 Hz spike-and-wave discharges (SWDs) detectable using electroencephalography (EEG). Current drug treatments are only partially effective and adverse side effects have spurred research into alternative treatment approaches. Recent research shows that positive allosteric modulation of the type-1 cannabinoid receptor (CB1R) reduces the frequency and duration of SWDs in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a model that recapitulates the SWDs in CAE. Here, we tested additional CB1R ago-PAMs, GAT591 and GAT593, for their potential in alleviating SWD activity in GAERS. In vitro experiments confirm that GAT591 and GAT593 exhibit increased potency and selectivity in cell cultures and behave as CB1R allosteric agonists and PAMs. To assess drug effects on SWDs, bilateral electrodes were surgically implanted in the somatosensory cortices of male GAERS and EEGs recorded for 4 h following systemic administration of GAT591 or GAT593 (1.0, 3.0 and 10.0 mg/kg). Both GAT591 and GAT593 dose-dependently reduced total SWD duration during the recording period. The greatest effect on SWD activity was observed at 10.0 mg/kg doses, with GAT591 and GAT593 reducing seizure duration by 36% and 34% respectively. Taken together, these results support the continued investigation of CB1R PAMs as a potential therapeutic to alleviate SWDs in absence epilepsy.
Langue d'origine | English |
---|---|
Pages (de-à) | 121-130 |
Nombre de pages | 10 |
Journal | IBRO Neuroscience Reports |
Volume | 12 |
DOI | |
Statut de publication | Published - juin 2022 |
Note bibliographique
Funding Information:Funding for the project was provided by a Saskatchewan Health Research Foundation (SHRF) Establishment Grant and a CIHR Partnership Grant with GlaxoSmithKline to RBL, and a CIHR Project Grant to JGH. This work was also supported by grant from National Institutes of Health (NIH) to GAT ( EY024717 ). Additional grant funding was provided by CIHR to TPS ( #10677 ) and a CURE Epilepsy Award to SMC.
Publisher Copyright:
© 2022
ASJC Scopus Subject Areas
- General Neuroscience
PubMed: MeSH publication types
- Journal Article